Compare VanEck Gold Miners ETF (GDX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Sanofi SA — how do they compare? VanEck Gold Miners ETF trades at $71.23, while Sanofi SA trades at $44.16 (market cap $103.94B). The key difference: Sanofi SA pays a 5.54% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals.
| GDX | SNY | |
|---|---|---|
52-Week High | $115.84 | $52.34 |
52-Week Low | $51.15 | $41.33 |
Market Cap | — | $103.94B |
Sector | — | Health |
Enterprise Value | — | $120.43B |
Dividend Yield | — | 5.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX (VanEck Gold Miners ETF) trades at $71.42, down 4.62% with bearish technical signals from moving averages. The fund faces competition from lower-fee gold ETFs while offering mining equity exposure with higher volatility. Recent portfolio changes include the addition of Aya Gold & Silver, potentially enhancing diversification. Technical indicators show neutral oscillators but overall bearish momentum with key support at $70.
The outlook remains cautious as gold miners navigate gold price volatility and fee competition. Upside potential exists if gold rebounds, but investors face risks from sector underperformance relative to physical gold. Analyst views are mixed, with some seeing value in discounted valuations while others highlight structural challenges in the mining ETF space.
Sanofi (SNY) trades at $44.11, up 2.15% today, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with a P/E of 19.37, net income margin of 15.95%, and consistent earnings beats in recent quarters. Recent FDA approval for Sarclisa's subcutaneous formulation and EU clearance for Cenrifki highlight pipeline progress, while a dividend of $2.42 per share underscores shareholder returns.
Outlook remains positive driven by Dupixent growth and new drug approvals, though risks include EU antitrust probes and competitive pressures. Analysts are mixed with 44% buy ratings, suggesting cautious optimism. The stock presents value with solid cash flow and profitability, but investors should monitor regulatory developments and pipeline execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
